Back to top
more

Sensus Healthcare (SRTS)

(Real Time Quote from BATS)

$5.20 USD

5.20
41,341

-0.05 (-0.95%)

Updated Aug 6, 2025 12:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $6.83, representing a -1.87% change from its previous close.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $7.21, representing a -1.77% change from its previous close.

Zacks Equity Research

Sensus Healthcare (SRTS) Surges 7.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Sensus Healthcare (SRTS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $7.10, marking a -1.53% move from the previous day.

Zacks Equity Research

Wall Street Bulls Look Optimistic About Sensus Healthcare (SRTS): Should You Buy?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Sensus Healthcare (SRTS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

Wall Street Analysts Believe Sensus Healthcare (SRTS) Could Rally 36.01%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 36% in Sensus Healthcare (SRTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Sensus Healthcare, Inc. (SRTS) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.

Zacks Equity Research

Here's What Could Help Sensus Healthcare (SRTS) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Sensus Healthcare (SRTS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Wall Street Analysts See a 39.66% Upside in Sensus Healthcare (SRTS): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Sensus Healthcare (SRTS) points to a 39.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

What Makes Sensus Healthcare (SRTS) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Sensus Healthcare (SRTS) delivered earnings and revenue surprises of 450% and 51.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hyperfine, Inc. (HYPR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hyperfine (HYPR) delivered earnings and revenue surprises of 0% and 7.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Astrana Health, Inc. (ASTH) Meets Q3 Earnings Estimates

by Zacks Equity Research

Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of 0% and 3.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Idexx Laboratories (IDXX) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 4.09% and 0.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) reachead $6.44 at the closing of the latest trading day, reflecting a +1.58% change compared to its last close.

Zacks Equity Research

Sensus Healthcare (SRTS) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $5.90, representing a +1.72% change from its previous close.

Zacks Equity Research

All You Need to Know About Sensus Healthcare (SRTS) Rating Upgrade to Strong Buy

by Zacks Equity Research

Sensus Healthcare (SRTS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) closed at $5.80 in the latest trading session, marking a -1.86% move from the prior day.

Zacks Equity Research

Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?

by Zacks Equity Research

Here is how BioLife Solutions, Inc. (BLFS) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Sensus Healthcare, Inc. (SRTS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Sensus Healthcare, Inc. (SRTS) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Zacks Equity Research

Recent Price Trend in Sensus Healthcare (SRTS) is Your Friend, Here's Why

by Zacks Equity Research

Sensus Healthcare (SRTS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Wall Street Analysts Think Sensus Healthcare (SRTS) Could Surge 65.68%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 65.7% upside potential for Sensus Healthcare (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Wall Street Analysts Think Sensus Healthcare (SRTS) Is a Good Investment: Is It?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Sensus Healthcare (SRTS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?